Matching articles for "Amyotrophic lateral sclerosis"

Relyvrio for ALS

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others)...
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole (Rilutek, and others) and edaravone (Radicava, Radicava ORS) were approved earlier.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):190-1 | Show Full IntroductionHide Full Introduction

In Brief: Edaravone Oral Suspension (Radicava ORS) for ALS (online only)

   
The Medical Letter on Drugs and Therapeutics • September 5, 2022;  (Issue 1658)
Radicava ORS, an oral suspension formulation of the free radical scavenger edaravone (Mitsubishi Tanabe Pharma), has been approved by the FDA for treatment of amyotrophic lateral sclerosis (ALS). An IV...
Radicava ORS, an oral suspension formulation of the free radical scavenger edaravone (Mitsubishi Tanabe Pharma), has been approved by the FDA for treatment of amyotrophic lateral sclerosis (ALS). An IV formulation of edaravone (Radicava) has been available since 2017.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):e1 | Show Full IntroductionHide Full Introduction

Cannabis and Cannabinoids

   
The Medical Letter on Drugs and Therapeutics • November 18, 2019;  (Issue 1585)
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of...
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-82 | Show Full IntroductionHide Full Introduction

Edaravone (Radicava) for ALS

   
The Medical Letter on Drugs and Therapeutics • November 6, 2017;  (Issue 1533)
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole...
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole (Rilutek, and generics) was approved in 1995. Edaravone was approved for treatment of ALS as Radicut in Japan and South Korea in 2015. It has been used in Japan and other Asian countries since 2001 for treatment of acute ischemic stroke.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):180-2 | Show Full IntroductionHide Full Introduction

Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect

   
The Medical Letter on Drugs and Therapeutics • June 13, 2011;  (Issue 1366)
The FDA has approved Nuedexta (Avanir), a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect....
The FDA has approved Nuedexta (Avanir), a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for oral treatment of pseudobulbar affect. The combination is the first treatment approved by the FDA for this indication. Studies to support the effectiveness of Nuedexta were performed in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS); the drug has not been shown to be safe or effective in other types of emotional lability.
Med Lett Drugs Ther. 2011 Jun 13;53(1366):46-7 | Show Full IntroductionHide Full Introduction

Coenzyme Q10

   
The Medical Letter on Drugs and Therapeutics • February 27, 2006;  (Issue 1229)
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination...
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Med Lett Drugs Ther. 2006 Feb 27;48(1229):19-20 | Show Full IntroductionHide Full Introduction

Riluzole for Amyotrophic Lateral Sclerosis

   
The Medical Letter on Drugs and Therapeutics • December 8, 1995;  (Issue 963)
The US Food and Drug Administration (FDA) has approved 'early access' use of riluzole (Rilutek - Rh ne-Poulenc Rorer) for treatment of amyotrophic lateral sclerosis (ALS). is the first drug to become...
The US Food and Drug Administration (FDA) has approved 'early access' use of riluzole (Rilutek - Rh ne-Poulenc Rorer) for treatment of amyotrophic lateral sclerosis (ALS). is the first drug to become available for treatment of this condition. The premarketing supply is limited; the manufacturer (1-800-798-7425) has enough on hand to treat 3,000 of the 25,000 patients with the disease in the USA, and those 3,000 have already been selected through a lottery. Similar arrangements have been made in several European countries. Riluzole is not available commercially in any country.
Med Lett Drugs Ther. 1995 Dec 8;37(963):113-4 | Show Full IntroductionHide Full Introduction